NEW YORK, November 13, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting AstraZeneca plc (NYSE: AZN), VIVUS, Inc. (NASDAQ: VVUS), The Cooper Companies, Inc. (NYSE: COO), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), and Amarin Corporation plc (NASDAQ: AMRN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
AstraZeneca plc Research Report
On October 31, 2013, AstraZeneca plc (AstraZeneca) announced the appointment of Marc Dunoyer as the Company's new CFO and also as an Executive Director of its Board, effective from November 1, 2013. The Company informed that Dunoyer in his new role will report to CEO of AstraZeneca, Pascal Soriot. "I'm delighted with Marc's appointment as CFO. Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience that will be critical in this role in the coming years as we focus on returning AstraZeneca to growth and achieving scientific leadership," said Soriot. The Full Research Report on AstraZeneca plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
VIVUS, Inc. Research Report
On November 5, 2013, VIVUS, Inc. (VIVUS) reported Q3 2013 financial results. In Q3 2013, the Company's net product revenue from sales of Qsymia was $6.4 million, and license revenue from the SPEDRA commercialization agreement with Menarini was $21.0 million, resulting in total revenue of $27.4 million, compared to total revenue of $41,000 in Q3 2012. Q3 2013 net loss was $48.2 million, or $0.48 per diluted share, compared with that of $40.4 million, or $0.40 per diluted share, in Q3 2012. "Our results for this quarter were disappointing, but we have made changes to improve our performance," said Seth H. Z. Fischer, CEO of VIVUS. "We strengthened our balance sheet by entering into partnerships with Auxilium and Menarini for commercialization of avanafil (STENDRA/SPEDRA), our erectile dysfunction drug. We have cut costs by reducing our workforce by 17%. We have initiated a process to seek European approval for Qsiva through the centralized procedure. Net product revenue from sales of Qsymia for obesity grew modestly, but we believe that recent growth in certified retail pharmacies, expanding reimbursement coverage and a more focused selling message will allow us to increase sales in 2014." The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
The Cooper Companies, Inc. Research Report
On November 7, 2013, The Cooper Companies, Inc. (Cooper) announced that it has completed the sale of its rigid gas permeable contact lens and solutions business in Japan, Aime, to Nippon Contact Lens Inc., effective from October 31, 2013. Cooper informed that Aime's revenues for full year FY 2013 were $25.3 million, and post divestiture the Company expects the transaction to be neutral to earnings per share. The Full Research Report on The Cooper Companies, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
ARIAD Pharmaceuticals, Inc. Research Report
On November 7, 2013, ARIAD Pharmaceuticals, Inc. (ARIAD) announced reduction of approximately 40% of its U.S. staff, following the Company's decision to temporarily suspend the marketing and commercial distribution of Iclusig (ponatinib) in the country. The Company informed that the workforce reduction is a part of its broad program to significantly reduce its corporate operating expenses and extend its cash position. ARIAD stated that it expects the staff reduction initiative to complete by the end of 2013 and to yield pre-tax savings of c.$26 million in 2014, while restructuring charges associated with the changes are expected to be c.$5 million in Q4 2013. The Full Research Report on ARIAD Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amarin Corporation plc Research Report
On November 7, 2013, Amarin Corporation plc (Amarin) reported its Q3 2013 financial results with net product revenues of $8.4 million. Q3 2013 GAAP net loss was $48.9 million, or $0.29 per basic and diluted loss per share, compared with GAAP net loss of $26.4 million, or $0.18 per basic and diluted loss per share, in Q3 2012. "We continue to witness the growth of awareness, Tier 2 managed care conversions, and prescription volume for Vascepa, seeing an increase of 58% in normalized TRxs from Q2 to Q3 of this year," said Joseph Zakrzewski, Chairman and CEO of Amarin. "We believe our dedicated and talented employees will be able to continue to grow our commercial business. We also believe that the efficacy and safety profile of Vascepa for its approved indication reflects a unique and favorably differentiated product which is well positioned to help clinicians provide improved care to their patients." The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner